CLINICAL USE

Advanced prostate cancer Endometriosis Precocious puberty Uterine fibroids prior to surgery

DOSE IN NORMAL RENAL FUNCTION

3–3.75 mg every 4 weeks; depends on preparation 11.25 mg every 3 months

PHARMACOKINETICS

  • Molecular weight                           : 1311.4
  • %Protein binding                           : No data
  • %Excreted unchanged in urine     : 3–14
  • Volume of distribution (L/kg)       : 92.4–115.8 litres
  • half-life – normal/ESRD (hrs)      : 7.5/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function, but monitor carefully
  • <10           : Dose as in normal renal function, but monitor carefully

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully
  • HD                     : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully
  • HDF/high flux   : Unknown dialysability. Dose as in normal renal function, but monitor carefully
  • CAV/VVHD      : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    With 2 mL diluent provided

    Route

    SC, IM

    Rate of Administration

    –

    Comments

    – .

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia